Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aDC1 vaccine + interferon alpha-2b + rintatolimod + celecoxib
- Development stage
- Unknown
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intradermal, Intravenous, Oral
01
Overview
This combination immunotherapy regimen, developed by Roswell Park Cancer Institute, is designed to overcome resistance to PD-1/PD-L1 checkpoint inhibitors in patients with HLA-A2+ melanoma. The regimen consists of an autologous alpha-type-1 polarized dendritic cell (aDC1) vaccine and a chemokine-modulating (CKM) component. The CKM component is a triple combination of interferon alpha-2b, rintatolimod (a double-stranded RNA TLR3 agonist), and celecoxib (a COX-2 inhibitor). The treatment aims to reprogram the tumor microenvironment by inducing the expression of T-cell-attracting chemokines (such as CXCL9, CXCL10, and CCL5) and reducing immunosuppressive factors like prostaglandin E2, thereby facilitating the infiltration of cytotoxic T lymphocytes into the tumor and restoring sensitivity to checkpoint blockade.
- Brand names
- AmpligenCelebrexIntron A
- Other names
- aDC1 + CKMaDC1-based treatment and chemokine modulationaDC-1-based treatment and chemokine modulationaDC 1-based treatment and chemokine modulationAlpha-type-1 polarized dendritic cell vaccine + interferon alpha-2b + rintatolimod + celecoxib
02
Targets
PSMB9 (Immunoproteasome subunit beta type-1i)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on aDC1 vaccine + interferon alpha-2b + rintatolimod + celecoxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aDC1 vaccine + interferon alpha-2b + rintatolimod + celecoxib.